AKASA vs Maverick AI
Two Autonomous Medical Coding vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| AKASA | Maverick AI | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Subscription sized by transaction volume | Not published · custom, tied to coding volume |
| Speed to go live | 60-90 days typical; longer multi-facility | customers typically live within 90 days |
| Automation model | Autonomous agents · GenAI automation with human review | Autonomous agents · direct-to-bill autonomous coding |
| Built for | Mid-size groups, Enterprise systems | Mid-size groups, Enterprise systems, Billing companies |
| Security posture | HITRUST, SOC 2 Type II, HIPAA | HIPAA |
| Company maturity | 8 yrs (est. 2018) | 7 yrs (est. 2019) |
| Financial backing | $205M · Series B | $11.5M (per PitchBook) · Seed plus strategic investment |
| Named customers | 2 named | 1 named |
| Published results | Specific numbers public | Specific numbers public |
| Documented integrations | 3 listed | 1 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick AKASA if you run a mid-size or large health system, ideally on Epic, and want generative AI working claims, auths, and coding in-house instead of outsourcing staff.
- Pick Maverick AI if you want charts coded and sent to billing without human coders, with 85 percent direct-to-bill.
AKASA
Generative AI for coding and revenue cycle operations
- Founded
- 2018
- HQ
- South San Francisco, CA
- Stage
- Series B
- Raised
- $205M
What it does
- Generative AI medical coding trained on clinical documentation
- Clinical documentation integrity (CDI) review at scale
- Automates prior auth status and claims follow-up work
- LLMs fine-tuned on customer clinical and financial data
- Surfaces missed codes and documentation gaps pre-bill
Where it's strong
- Cleveland Clinic co-developed and is now deploying its GenAI CDI product across all US locations, a rare tier-one clinical validation.
- Deep pockets ($205M raised) and deployment across 650+ hospitals reduce vendor-viability risk.
- Focus on mid-revenue-cycle (coding plus CDI) fits health systems that want one vendor for both.
What buyers should weigh
- The company pivoted from RPA-style automation to generative AI, so ask which product generation you are actually buying.
- Flagship proof points are large academic systems; fit and pricing for smaller hospitals is less proven.
- Last disclosed raise was 2022, so probe current burn and roadmap funding.
Named customers
Cleveland Clinic · Duke University Health System
Integrations
Maverick AI
Real-time autonomous medical coding for revenue cycle teams
- Founded
- 2019
- HQ
- n/a
- Stage
- Seed plus strategic investment
- Raised
- $11.5M (per PitchBook)
What it does
- Real-time autonomous coding via the mCoder platform
- 85%+ direct-to-bill rate without human touch
- Codes most cases in seconds
- Reported 95% coding accuracy
- Streams coded results straight to billing systems
Where it's strong
- Real-time coding with a published 85%+ direct-to-bill rate, ahead of the batch processing common in the category.
- Proven at national scale through the RadNet implementation across US imaging sites.
- The Infinx investment and partnership give it a distribution channel into established RCM operations.
What buyers should weigh
- Widely cited reports of a $47M 2025 raise belong to competitor Nym, not Maverick; Maverick's disclosed funding is about $11.5M, so weigh vendor financial durability.
- Public proof points are concentrated in radiology; ask for evidence in other specialties.
- Roughly 15% of cases still route to human coders, so plan for a review workflow.
Named customers
RadNet
Integrations
Compare against the rest of Autonomous Medical Coding
Deciding between these two?
First Pass tracks Autonomous Medical Coding every week: funding, launches, and what changed since this page was written.